Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice.
COVID-19
TGF-β1
bleomycin
pulmonary fibrosis
remdesivir (RDV)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
04
2021
accepted:
13
08
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Pulmonary fibrosis is a known sequela of severe or persistent lung damage. Existing clinical, imaging and autopsy studies have shown that the lungs exhibit a pathological pulmonary fibrosis phenotype after infection with coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pulmonary fibrosis may be one of the most serious sequelae associated with coronavirus disease 2019 (COVID-19). In this study, we aimed to examine the preventative effects of the antiviral drug remdesivir on pulmonary fibrosis. We used a mouse model of bleomycin-induced pulmonary fibrosis to evaluate the effects of remdesivir on pulmonary fibrosis
Identifiants
pubmed: 34512328
doi: 10.3389/fphar.2021.692346
pii: 692346
pmc: PMC8427522
doi:
Types de publication
Journal Article
Langues
eng
Pagination
692346Informations de copyright
Copyright © 2021 Li, Liu, Cui, Liang, Bi, Li, Miao, Zhang, Li, Zhou and Yang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochem Pharmacol. 2020 Aug;178:114097
pubmed: 32535102
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Curr Opin Pulm Med. 2012 Sep;18(5):517-23
pubmed: 22854509
Am J Respir Cell Mol Biol. 2017 May;56(5):667-679
pubmed: 28459387
Viruses. 2019 Apr 04;11(4):
pubmed: 30987343
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Eur Respir J. 2020 Apr 23;55(4):
pubmed: 32269090
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Chest. 2005 Jun;127(6):2119-24
pubmed: 15947329
J Infect. 2020 Apr;80(4):394-400
pubmed: 32109443
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14895-900
pubmed: 15469929
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Indian J Radiol Imaging. 2017 Jul-Sep;27(3):342-349
pubmed: 29089687
Lancet Respir Med. 2020 Aug;8(8):807-815
pubmed: 32422178
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Chest. 1995 Apr;107(4):1062-73
pubmed: 7705118
Dtsch Arztebl Int. 2020 Jul 20;117(29-30):500-506
pubmed: 32865490
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32165401
Front Pharmacol. 2019 Sep 13;10:1021
pubmed: 31572194
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Proc Am Thorac Soc. 2012 Jul;9(3):111-6
pubmed: 22802283
Lancet. 2011 Dec 3;378(9807):1949-61
pubmed: 21719092
N Engl J Med. 2011 Apr 7;364(14):1293-304
pubmed: 21470008
Am J Respir Crit Care Med. 2006 Apr 1;173(7):769-76
pubmed: 16415276
Chest. 2011 Jun;139(6):1340-1346
pubmed: 21330382
Eur J Pharmacol. 2019 Dec 1;864:172712
pubmed: 31586469
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Respir Res. 2002;3:3
pubmed: 11806838
Ther Adv Respir Dis. 2010 Dec;4(6):367-88
pubmed: 20952439
AJR Am J Roentgenol. 2020 Jun;214(6):1287-1294
pubmed: 32134681
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Eur Radiol. 2020 Jun;30(6):3306-3309
pubmed: 32055945
J Clin Invest. 2004 Jul;114(2):291-9
pubmed: 15254596
Am J Respir Cell Mol Biol. 2016 May;54(5):647-55
pubmed: 26796672